Research And Development Arrangement, Contract To Perform For Others, Marketing Approval, Termination Period

No definition available.

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMarketingApprovalTerminationPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Maximum Amount

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix:	mrna_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Arrangement, Contract To Perform For Others, Number Of Extension Periods

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfExtensionPeriods
Namespace Prefix:	mrna_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Payment Received, Research Extension Period

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentReceivedResearchExtensionPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Research Extension Period

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Research Extension Period Elected

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchExtensionPeriodElected
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research And Development Arrangement, Contract To Perform For Others, Termination Period

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
Namespace Prefix:	mrna_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_StrategicCollaborationAndLicenseAgreementWithVertexPharmaceuticalsIncorporatedAndVertexPharmaceuticalsEuropeLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesSubsequentProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_ResearchAndDevelopmentFundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements - Vertex – 2016 Strategic Alliance in Cystic Fibrosis (Details)	1 Months Ended		12 Months Ended
	Jul. 31, 2019 USD ($) extension_period	Jul. 31, 2016 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Remaining performance obligations			$ 87,225,000
Increase to the transaction price			(7,100,000)
Deferred revenue			3,867,193,000	$ 63,310,000
Additions			4,009,960,000
Vertex Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research extension period elected	6 months
Total collaboration revenue	$ 2,000,000.0		4,500,000
Payment received, research extension period	18 months
Number of extension periods \| extension_period	2
Research extension period	1 year
Proceeds from equity investment	$ 20,000,000.0
Termination period	90 days
Termination period upon marketing approval	180 days
Remaining performance obligations				24,400,000
Increase to the transaction price			8,600,000
Additions		$ 20,000,000.0
Vertex Agreement \| Development Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	$ 55,000,000.0
Vertex Agreement \| Regulatory Milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	220,000,000.0
Vertex Agreement \| Regulatory Milestones, Subsequent Products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Estimated arrangement consideration	$ 3,000,000.0
Vertex Agreement \| Upfront payment
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Remaining performance obligations			2,000,000.0	20,000,000.0
Vertex Agreement \| Research and development
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Remaining performance obligations			$ 2,500,000	$ 4,400,000